| Literature DB >> 31569593 |
Xiao-Dong Li1,2, Xiao-Ming Li3,4,5, Xiu-Li Yin6, Xin Li7,8,9, Bin-Gui Wang10,11,12.
Abstract
Two new antimicrobial bisabolane-type sesquiterpenoid derivatives, ent-aspergoterpenin C (compound 1) and 7-O-methylhydroxysydonic acid (2), and two new butyrolactone-type monoterpenoids, pestalotiolactones C (3) and D (4), along with a known monoterpenoid pestalotiolactone A (5) and four known bisabolane sesquiterpenoids (6-9), were isolated and identified from the deep-sea sediment-derived fungus Aspergillus versicolor SD-330. The structures of these compounds were elucidated on the basis of spectroscopic analysis, and the absolute configurations of the new compounds 1-4 were determined by the combination of NOESY and TDDFT-ECD calculations and X-ray crystallographic analysis. Additionally, we first determined and reported the absolute configuration of the known monoterpenoid pestalotiolactone A (5) through the X-ray crystallographic experiment. All of these isolated compounds were evaluated for antimicrobial activities against human and aquatic pathogenic bacteria. Compounds 1, 2, 6 and 9 exhibited selective inhibitory activities against zoonotic pathogenic bacteria such as Escherichia coli, Edwardsiella tarda, Vibrio anguillarum and V. harveyi, with MIC values ranging from 1.0 to 8.0 μg/mL.Entities:
Keywords: Aspergillus versicolor; antimicrobial activity; bisabolane-type sesquiterpenoids; deep-sea sediment-derived fungus; monoterpenoids
Mesh:
Substances:
Year: 2019 PMID: 31569593 PMCID: PMC6836274 DOI: 10.3390/md17100563
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–9.
1H and 13C data of compounds 1 and 2 (measured in DMSO-d6).
| No. | 1 | 2 | ||
|---|---|---|---|---|
| 1 | - | 155.0, qC | - | 154.4, qC |
| 2 | - | 138.6, qC | - | 134.2, qC |
| 3 | 7.44, d (8.1) | 127.1, CH | 7.30, d (8.0) | 127.3, CH |
| 4 | 7.34, dd (8.1, 1.6) | 119.2, CH | 7.35, d (8.0) | 119.7, CH |
| 5 | - | 128.7, qC | - | 132.2, qC |
| 6 | 7.31, d (1.6) | 116.4, CH | 7.36, s | 116.9, CH |
| 7 | - | 74.6, qC | - | 79.5, qC |
| 8a | 1.93, dt (13.0, 4.4) | 41.8, CH2 | 1.87, t (11.4) | 38.4, CH2 |
| 8b | 1.65, dt (13.0, 4.0) | - | 1.76, t (11.4) | - |
| 9a | 1.30, m | 18.5, CH2 | 1.19, m | 18.2, CH2 |
| 9b | 1.02, m | - | 1.03, m | - |
| 10 | 1.23, m | 44.0, CH2 | 1.22, t (12.3) | 43.8, CH2 |
| 11 | - | 68.7, qC | - | 68.6, qC |
| 12 | 0.97, s | 29.3, CH3 | 0.97, s | 29.2, CH3 |
| 13 | 0.95, s | 29.2, CH3 | 0.97, s | 29.2, CH3 |
| 14 | 1.50, s | 28.1, CH3 | 1.54, s | 22.2, CH3 |
| 15 | - | 166.2, qC | - | 167.9, qC |
| 15-COO | 3.80, s | 51.8, CH3 | - | - |
| 7-O | - | - | 3.15, s | 49.4, CH3 |
a Measured at 500 MHz; b Measured at 125 MHz.
Figure 2Key COSY (bold lines) and HMBC (arrows) correlations for compounds 1–4.
Figure 3Experimental and calculated ECD spectra of compounds 1 and 2.
1H and 13C data of compounds 3 and 4 (measured in DMSO-d6).
| No. | 3 | 4 | ||
|---|---|---|---|---|
| 1 | - | 178.1, qC | - | 179.5, qC |
| 2 | - | 75.6, qC | 2.89, m | 38.2, CH |
| 3 | 2.72, dd (8.9, 7.3) | 53.9, CH | 2.99, m | 44.3, CH |
| 4 | 1.84, m | 46.0, CH | 1.78, m | 46.0, CH |
| 5 | - | 77.5, qC | - | 77.8, qC |
| 6α | 1.91, d (14.3) | 45.5, CH2 | 1.92, d (14.3) | 45.7, CH2 |
| 6β | 1.73, dd (14.3, 6.5) | - | 1.81, dd (14.3, 6.9) | - |
| 7 | 4.93, t (6.8) | 80.3, CH | 4.80, t (6.7) | 81.0, CH |
| 8 | 1.39, s | 21.6, CH3 | 1.22, d (7.3) | 12.3, CH3 |
| 9 | 1.02, d (7.5) | 9.7, CH3 | 0.98, d (7.5) | 10.2, CH3 |
| 10 | 1.08, s | 24.8, CH3 | 1.11, s | 26.0, CH3 |
a Measured at 500 MHz; b Measured at 125 MHz.
Figure 4Key NOESY correlations (blue lines: β-orientation; blue dotted lines: α-orientation) for compounds 3–5.
Figure 5X-ray structures of compounds 3 and 5.
Figure 6Experimental and calculated ECD spectra of compounds 3–5.
Antimicrobial activities of compounds 1–9 (MIC, μg/mL) a.
| Strains | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Positive Control |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 4.0 | 2.0 | – | – | – | 1.0 | – | 32 | 16 | 2.0 |
|
| – | 8.0 | 16 | – | – | 4.0 | 16 | 32 | 8.0 | 2.0 |
|
| 8.0 | 4.0 | – | 32 | – | 4.0 | 32 | – | 8.0 | 2.0 |
|
| 8.0 | 32 | – | – | – | 8.0 | – | – | – | 2.0 |
|
| – | 4.0 | 32 | – | 32 | 4.0 | 32 | 32 | 32 | 0.5 |
|
| 8.0 | 8.0 | – | 32 | 32 | 4.0 | 16 | 32 | 16 | 4.0 |
|
| 8.0 | 8.0 | 16 | – | – | 8.0 | – | – | 32 | 1.0 |
a (−) = MIC > 32 μg/mL, b Chloramphenicol as positive control.